Efgartigimod - argenx

Drug Profile

Efgartigimod - argenx

Alternative Names: ARGX-113

Latest Information Update: 08 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator arGEN-X
  • Developer argenx
  • Class Immunoglobulin Fc fragments; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Neonatal Fc receptor-antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myasthenia gravis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Idiopathic thrombocytopenic purpura; Myasthenia gravis; Pemphigus vulgaris

Most Recent Events

  • 02 Aug 2018 argenx plans an open-label extension trial in Myasthenia gravis
  • 24 Jul 2018 Updated immunogenicity data from a phase I trial in volunteers released by argenx
  • 21 Jun 2018 Interim safety and adverse events data from a phase II trial in Pemphigus vulgaris released by argenx
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top